/AKBA

Akebia Therapeutics Inc

AKBA

$0.95USD↑+0.55%+0.01 today

MARKET CAP

263.7M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1

$3

AI Summary

Stalk

StalkMedium

Despite the long-term downtrend, AKBA’s early Stage 1 base and the Bullish Pivot Point suggest upward mean-reversion potential. Price is currently extended above the rising short EMAs and testing resistance at the 50-day SMA without clear exhaustion, so execution should be deferred. We will await a pullback into the 9/21 EMA support zone near the base lows before initiating participation.

↑Vafcio net product revenue rose 60% YoY to $21.3M in Q2 2026
↑Patient enrollment grew 41% QoQ to over 10,500 active users
↓Total revenues fell 21% YoY to $49.1M, driven by Arixia declines

Full analysis →

Buying

7

institutions

Selling

3

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	19.99 M	22.78 M	+1.29 M	-12.3%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	9.15 M	10.43 M	+7.36 M	+318.7%	0.00%
MM Millennium Management LLC Q2 2026	BUY	3.20 M	3.64 M	+811.89 K	+9.9%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	1.98 M	2.26 M	+255.49 K	-5.8%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	1.22 M	1.40 M	+-609.16 K	-45.2%	0.00%
EP Eversept Partners, LP Q2 2026	BUYNEW	427.10 K	486.89 K	+427.10 K	+0.0%	0.03%
JC Jpmorgan Chase & Co Q2 2026	BUY	269.04 K	298.63 K	+154.99 K	+98.4%	0.00%
MG Man Group Plc Q2 2026	SELL	155.40 K	177.15 K	+-102.46 K	-50.6%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUY	63.75 K	72.67 K	+37.73 K	+100.9%	0.00%
JH Janus Henderson Group Plc Q1 2026	SELL	0.00	0.00	+-704.02 K	-100.0%	0.00%